Medical device company ResMed (NYSE: RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 10.8% year on year to $1.43 billion. Its non-GAAP profit of $2.86 per share was 2.2% above analysts’ consensus estimates.

Is now the time to buy RMD? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

ResMed’s first quarter saw the company deliver revenue and earnings above Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s performance to strong growth in its masks and accessories segment, as well as the ongoing rollout of the AirSense 11 platform in new markets like Latin America and China. CEO Michael J. Farrell highlighted operational improvements in supply chain management and logistics, which contributed to margin expansion, and noted the impact of digital and educational initiatives in broadening sleep apnea awareness and diagnosis. The quarter also included the announced retirement of long-serving CFO Brett A. Sandercock, with Aaron Blumer set to assume the role.

Looking ahead, management’s guidance is shaped by expectations for continued momentum in mask and device demand, ongoing investments in digital health, and the integration of the newly acquired Noctrix Health. CEO Michael J. Farrell emphasized the potential of the GLP-1 drug trend as a “once-in-a-generation demand-gen opportunity,” predicting that both pharmaceutical and device therapies will drive more patients into the ResMed ecosystem. Management also anticipates further gross margin improvement through ongoing supply chain efficiencies, though they acknowledged potential headwinds from higher component costs and global macroeconomic uncertainties.

Key Insights from Management’s Remarks

ResMed’s first quarter benefited from robust demand for its new mask technologies, increased adherence rates, global expansion of core platforms, and operational discipline, while leadership transitions and a strategic acquisition also shaped results.

• Mask portfolio outperformance: Adoption of the AirTouch N30i and new fabric-based masks led to higher patient adherence rates and drove double-digit growth in mask sales, with management highlighting that fabric masks achieved 6% higher 90-day compliance than silicone equivalents.
• Global expansion of AirSense 11: The rollout of the AirSense 11 device platform into Latin America and China contributed to device segment growth, with region-specific digital ecosystems, such as WeChat integration in China, enhancing local patient engagement.
• GLP-1 drug trend as tailwind: Management’s real-world data analyses indicated that patients combining CPAP therapy with GLP-1 medications had higher initiation and adherence rates, supporting mask resupply growth and positioning ResMed to benefit from broader awareness campaigns by pharmaceutical partners.
• Noctrix Health acquisition: The company announced the acquisition of Noctrix Health, whose FDA-cleared NIDRA device for restless leg syndrome addresses a large, overlapping patient population and is expected to deliver faster growth and higher margins than ResMed’s legacy business.
• Leadership transition: CFO Brett A. Sandercock’s retirement and the appointment of Aaron Blumer, with global experience from Exact Sciences, 3M, and Baxter, marked a significant leadership change, with management emphasizing continuity in financial discipline and strategic execution.

Drivers of Future Performance

Management expects continued demand for masks and devices, supply chain efficiency, and new partnerships to drive revenue and margin expansion, while acknowledging cost inflation and integration risks.

• Mask innovation and market share: Ongoing development and adoption of premium fabric-based masks, along with the full-face F30i line, are expected to support share gains and adherence improvements, especially as new clinical evidence links sleep apnea treatment to reduced risk of neurological diseases.
• Integration of Noctrix Health: The newly acquired Noctrix business, focused on noninvasive restless leg syndrome therapy, is projected to accelerate growth and expand ResMed’s addressable market, though management noted initial dilution to non-GAAP EPS and the need for investment in sales, marketing, and R&D.
• Supply chain and cost management: While gross margin improvements are anticipated through logistics and manufacturing efficiencies, management acknowledged headwinds from rising component and fuel costs, as well as the broader geopolitical environment, requiring ongoing operational discipline to sustain profitability.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace of adoption and integration for Noctrix Health’s NIDRA device, (2) further expansion and real-world uptake of new fabric-based masks and AirSense 11 in recently entered markets, and (3) the impact of GLP-1 therapy awareness on overall patient funnel growth. Execution on maintaining supply chain efficiency and profitability amid rising input costs will remain key signposts for progress.

ResMed currently trades at $211.75, in line with $213.81 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.